Physician profile
Steven Teplitz
NPI 1003815960
$4,998.15
in general payments reported to CMS, 2019-2025
27 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 95% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $355 · 2021: $626 · 2022: $267 · 2023: $861 · 2024: $986 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,071.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,395.84 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Janssen Biotech, INC. | $648.46 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $532.36 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $458.53 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Intercept Pharmaceuticals, INC. | $345.79 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $224.19 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $207.42 | 2019-2025 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $199.65 | 2019-2024 | Dificid |
| Vivus LLC | $156.65 | 2024-2025 | Qsymia, Pancreaze |
| Ardelyx, INC. | $128.17 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $86.84 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $85.55 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $83.09 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $73.27 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $65.53 | 2023-2024 | Talicia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $47.13 | 2021 | |
| Exact Sciences Corporation | $31.73 | 2025 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $30.00 | 2025 | Suflave |
| Qiagen, LLC | $29.56 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $28.87 | 2023 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.12 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $21.57 | 2020 | |
| Pfizer INC. | $21.37 | 2019 | |
| Capsovision, INC. | $19.82 | 2024 | Capsocam Plus |
| Ipsen Biopharmaceuticals, INC | $17.97 | 2024 | |
| Echosens North America, INC. | $17.00 | 2023 | Fibroscan |
| Micro-Tech Endoscopy USA, INC. | $14.67 | 2024 | Lesionhunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Teplitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.